SCZD2
MCID: SCH085
MIFTS: 33

Schizophrenia 2 (SCZD2)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia 2

MalaCards integrated aliases for Schizophrenia 2:

Name: Schizophrenia 2 56 12 73 15 71
Sczd2 56 12 73
Schizophrenia Susceptibility Locus, Chromosome 11q-Related 56
Schizophrenia Susceptibility Locus Chromosome 11q-Related 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0070078
OMIM 56 603342
MeSH 43 D012559
MedGen 41 C1864010
UMLS 71 C1864010

Summaries for Schizophrenia 2

UniProtKB/Swiss-Prot : 73 Schizophrenia 2: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

MalaCards based summary : Schizophrenia 2, also known as sczd2, is related to schizophrenia 1 and schizophrenia. An important gene associated with Schizophrenia 2 is SCZD2 (Schizophrenia Disorder 2). The drugs Insulin, Globin Zinc and insulin have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and cerebellum.

Disease Ontology : 12 A schizophrenia that has material basis in an autosomal dominant mutation of SCZD2 on chromosome 11q14-q21.

More information from OMIM: 603342

Related Diseases for Schizophrenia 2

Graphical network of the top 20 diseases related to Schizophrenia 2:



Diseases related to Schizophrenia 2

Symptoms & Phenotypes for Schizophrenia 2

Clinical features from OMIM:

603342

Drugs & Therapeutics for Schizophrenia 2

Drugs for Schizophrenia 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 68, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Insulin, Globin Zinc Phase 4
2 insulin Phase 4
3 Hypoglycemic Agents Phase 4
4
Fluphenazine Approved Phase 3 69-23-8 3372
5
Asenapine Approved Phase 3 65576-45-6, 85650-56-2 3001386
6
Haloperidol Approved Phase 3 52-86-8 3559
7
Cariprazine Approved, Investigational Phase 3 839712-12-8 11154555
8
Clozapine Approved Phase 3 5786-21-0 2818
9
Kynurenic acid Investigational Phase 2, Phase 3 492-27-3 3845
10 Omega 3 Fatty Acid Phase 2, Phase 3
11 Antidepressive Agents Phase 3
12 Fluphenazine depot Phase 3
13 Quetiapine Fumarate Phase 3 111974-72-2
14 Fluphenazine enanthate Phase 3
15 Gastrointestinal Agents Phase 3
16 Antiemetics Phase 3
17 Haloperidol decanoate Phase 3
18 Psychotropic Drugs Phase 3
19 Antipsychotic Agents Phase 3
20 Adrenergic Agents Phase 3
21 Atomoxetine Hydrochloride Phase 3
22
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
23
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
24
Galantamine Approved Phase 2 357-70-0 9651
25
Levodopa Approved Phase 2 59-92-7 6047
26
Carbidopa Approved Phase 2 28860-95-9 34359
27
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
28
Icodextrin Approved, Investigational Phase 2 337376-15-5
29
Polyestradiol phosphate Approved Phase 2 28014-46-2
30 Cholinesterase Inhibitors Phase 2
31 Immunologic Factors Phase 2
32 Antiparkinson Agents Phase 2
33 Adjuvants, Immunologic Phase 2
34 Carbidopa, levodopa drug combination Phase 2
35 Dihydroxyphenylalanine Phase 2
36 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2
37 Hormones Phase 2
38 Estradiol 17 beta-cypionate Phase 2
39 Estradiol 3-benzoate Phase 2
40 Hormone Antagonists Phase 2
41 Contraceptive Agents Phase 2
42 Estrogens Phase 2
43
leucovorin Approved 58-05-9 6006 143
44
Methylcobalamin Approved, Investigational 13422-55-4
45
Hydroxocobalamin Approved 13422-51-0 15589840 11953898
46
Lithium carbonate Approved 554-13-2
47
Nicotinamide Approved, Investigational 98-92-0 936
48
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
49
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
50
Cyanocobalamin Approved, Nutraceutical 68-19-9 44176380
51
Niacin Approved, Investigational, Nutraceutical 59-67-6 938
52
Cobalamin Experimental 13408-78-1 6857388
53 Trace Elements
54 Micronutrients
55 Vitamins
56 Vitamin B Complex
57 Vitamin B 12
58 Hematinics
59 Vitamin B12
60 Nutrients
61 Folate
62 Vitamin B9
63 Anticonvulsants
64 Nicotinic Acids
65 Vitamin B3
66 Acidophilus
67 Chlorpheniramine, phenylpropanolamine drug combination
68 Bifidobacterium

Interventional clinical trials:

(showing 42, show less)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine Unknown status NCT02286206 Phase 4 Clozapine
2 Intranasal Insulin Treatment in Patients With Schizophrenia Completed NCT00575666 Phase 4 Insulin or Placebo
3 Safety and Tolerability of Varenicline When Used for Smoking Cessation/Reduction in Individuals With Severe and Persistent Mental Illness: An Open Label Pilot Trial Withdrawn NCT00702793 Phase 4 Varenicline
4 Ethyl-EPA Treatment of Prodromal Patients Completed NCT00634361 Phase 2, Phase 3 ethyl-eicosapentaenoic acid
5 New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia Completed NCT00161018 Phase 3 Quetiapine, Risperidone, Fluphenazine
6 A Multicenter, Randomized, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of Asenapine Using Haloperidol Positive Control in Subjects Who Complete Protocol 041023 [NCT00156104] Completed NCT00156065 Phase 3 Haloperidol;Asenapine;Asenapine
7 Neuroimaging of Tryptophan Challenge in People With Schizophrenia and Healthy Controls Completed NCT02067975 Phase 2, Phase 3 Tryptophan;Placebo
8 A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia Recruiting NCT03593213 Phase 3 Cariprazine;Placebo
9 Correlation of Phenotype, Genotype and Clinical Efficacy/Toxicity of Clozapine Augmented by Atomoxetine for Treatment Refractory Schizophrenia (CAPG Study) Terminated NCT00216281 Phase 3 Clozapine augmented with atomoxetine up to 40 mg or placebo
10 Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study to Compare the Effectiveness of Brexpiprazole to That of Risperidone in Adult Patients With Schizophrenia Withdrawn NCT02758067 Phase 3 brexpiprazole;risperidone
11 A Randomized Trial Administering Oxytocin vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia and Schizo-affective Disorder Unknown status NCT01598623 Phase 2 Oxytocin
12 Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia Completed NCT01012167 Phase 2 Oxytocin;Galantamine
13 Augmentation of Antipsychotics With L-Dopa (Sinemet) Completed NCT01636037 Phase 2 levodopa/carbidopa (generic version of Sinemet)
14 Multisite Double-Blind Randomized Controlled Study of Estradiol Plus Antipsychotic Versus Placebo Plus Antipsychotic in the Treatment of Psychotic Symptoms in Women With Schizophrenia Completed NCT00357006 Phase 2 Estradiol;Estradiol
15 Shiatsu Adjuvant Therapy And Placebo For Schizophrenia:a Double Blind Study Unknown status NCT00788970
16 Relationships of One-carbon Cycle Pathway With Psychopathology and Metabolic Abnormalities in Patients With Schizophrenia and Potential Intervention Strategy With Folic Acid and Vitamin B12 Unknown status NCT02916121
17 Cognitive Remediation for Perceptual Deficits in Schizophrenia Unknown status NCT02337439
18 Dialectical Behavioral Therapy (DBT) Based Skills Group for Children With Emotional Dysregulation and Their Parents Unknown status NCT01299740
19 Effect of rTMS Over the Medial Cerebellum on Negative Symptoms and Cognitive Dysmetria in Subjects With Treatment Refractory Schizophrenia Unknown status NCT02242578
20 A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES) Unknown status NCT00173069
21 A Study on Risk Mutations of Vulnerability Genes of Schizophrenia Unknown status NCT00155207
22 Art Therapy for Symptom Reduction in Acute Schizophrenia - a Randomised Controlled Trial (Kunsttherapie Zur Symptomreduktion Bei Akuter Schizophrenie - Eine Randomisierte Kontrollierte Pilotstudie) Completed NCT01622166
23 Prevalence of and Factors Associated With Metabolic Syndrome in Patients With Schizophrenia Completed NCT01587521
24 A Genetic Linkage Study of Schizophrenia Completed NCT00155688
25 Effects of Oxytocin on Neural Activation Patterns During Social Cognitive Tasks in Patients With Schizophrenia Completed NCT02568709 Early Phase 1 Oxytocin;Saline Nasal Spray
26 The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong: an Open Label Randomized Controlled Trial Completed NCT02435784
27 Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia Completed NCT00770237
28 2-Way Pagers to Improve Schizophrenia Medication Adherence Completed NCT00392236
29 Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia Completed NCT02775864 Antipsychotic;Antidepressant;Benzodiazepine;Mood stabilizer
30 The Impact of Yoga Supplementation on Cognitive Function Among Indian Outpatients With Schizophrenia Completed NCT01879709
31 Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects Completed NCT02575209
32 Brain Circuits in Schizophrenia and Smoking Completed NCT01369966
33 Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence Completed NCT01037075
34 Implementing Patient-Centered Decision Support for Mental Health Completed NCT02183844
35 Implementing Effective, Collaborative Care for Schizophrenia Completed NCT00137280
36 A Positional Cloning Study on Schizophrenia Completed NCT00155649
37 Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios Completed NCT00155506
38 Transcranial Direct Current Stimulation (tDCS) Studies of Cognition, Oscillations and GABA Levels in Schizophrenia Recruiting NCT04267003
39 A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolar Disorder Recruiting NCT03379597 Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)
40 Overcoming Psychomotor Slowing in Psychosis (OCoPS-P): a 3-week, Randomized, Double-blind, Placebo-controlled Trial of add-on Repetitive Transcranial Magnetic Stimulation for Psychomotor Slowing in Psychosis Recruiting NCT03921450 Placebo
41 Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms on Schizophrenia: Controlled, Randomised, Double Blind Trial Recruiting NCT03284138
42 A Study on Etiological Factors of Schizophrenia Terminated NCT00155636

Search NIH Clinical Center for Schizophrenia 2

Genetic Tests for Schizophrenia 2

Anatomical Context for Schizophrenia 2

MalaCards organs/tissues related to Schizophrenia 2:

40
Brain, Cortex, Cerebellum, Testes, Prefrontal Cortex, Eye, Placenta

Publications for Schizophrenia 2

Articles related to Schizophrenia 2:

(showing 230, show less)
# Title Authors PMID Year
1
Schizophrenia-associated chromosome 11q21 translocation: identification of flanking markers and development of chromosome 11q fragment hybrids as cloning and mapping resources. 61 56
8383424 1993
2
A genetic association study of chromosome 11q22-24 in two different samples implicates the FXYD6 gene, encoding phosphohippolin, in susceptibility to schizophrenia. 56
17357072 2007
3
Family-based association study of schizophrenia with 444 markers and analysis of a new susceptibility locus mapped to 11q13.3. 56
15108173 2004
4
Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23. 56
11179014 2001
5
Genome scan of schizophrenia. 56
9619145 1998
6
Physical mapping of a glutamate receptor gene in relation to a balanced translocation associated with schizophrenia in a large Scottish family. 56
9460801 1997
7
An allelic association study of two polymorphic markers in close proximity to a balanced translocation t(1:11) that co-segregates with mental illness. 56
9460802 1997
8
Linkage results on 11Q21-22 in Eastern Quebec pedigrees densely affected by schizophrenia. 56
8825888 1995
9
A contiguous clone map over 3 Mb on the long arm of chromosome 11 across a balanced translocation associated with schizophrenia. 56
7490076 1995
10
Exclusion of linkage of schizophrenia to the gene for the dopamine D2 receptor (DRD2) and chromosome 11q translocation sites. 56
7480434 1995
11
Genetic linkage analysis of schizophrenia using chromosome 11q13-24 markers in Israeli pedigrees. 56
7485242 1995
12
Direct microdissection and microcloning of a translocation breakpoint region, t(1;11)(q42.2;q21), associated with schizophrenia. 56
7736785 1995
13
Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome 11q in 112 Irish multiplex families. 56
8439241 1993
14
A linkage study of chromosome 11q in schizophrenia. 56
8439242 1993
15
Association within a family of a balanced autosomal translocation with major mental illness. 56
1973210 1990
16
A balanced chromosomal translocation partially co-segregating with psychotic illness in a family. 56
2349309 1990
17
SZDB2.0: an updated comprehensive resource for schizophrenia research. 61
32385526 2020
18
The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. 61
32343342 2020
19
A pilot randomised trial comparing a mindfulness-based stress reduction course, a locally-developed stress reduction intervention and a waiting list control group in a real-life municipal health care setting. 61
32228533 2020
20
The Role of Inflammation in the Treatment of Schizophrenia. 61
32256401 2020
21
Analysis of the expression of BAX, BCL2, BIRC6, CASP3, CASP9 apoptosis genes during the first episode of schizophrenia. 61
32017818 2019
22
HIV, schizophrenia, and all-cause mortality: A population-based cohort study of individuals accessing universal medical care from 1998 to 2012 in British Columbia, Canada. 61
31255392 2019
23
International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis. 61
31054641 2019
24
Mental illness stigma among Pacific Islanders. 61
30716597 2019
25
[Reaction on 'Cariprazine for acute and maintenance treatment of schizophrenia']. 61
31907907 2019
26
Bilateral Calcification of Basal Ganglia in a Patient with Duplication of Both 11q13.1q22.1 and 4q35.2 with New Phenotypic Features. 61
31715598 2019
27
Mental health multimorbidity and poor quality of life in patients with schizophrenia. 61
29709490 2018
28
Associations among domains of self-disturbance in schizophrenia. 61
29913377 2018
29
A review of impaired visual processing and the daily visual world in patients with schizophrenia. 61
30214081 2018
30
Schizophrenia as Potential Trigger for Melanoma Development and Progression! The Psycho-Neuro-Endocrine-Oncology (P.N.E.O) Network! 61
30159073 2018
31
Abnormal brain activation during threatening face processing in schizophrenia: A meta-analysis of functional neuroimaging studies. 61
29153447 2018
32
Multinational comparative cross-sectional survey of views of medical students about acceptable terminology and subgroups in schizophrenia. 61
29880569 2018
33
Electroretinographic anomalies in schizophrenia. 61
29745706 2018
34
Abdominal Vagal Afferents Modulate the Brain Transcriptome and Behaviors Relevant to Schizophrenia. 61
29326171 2018
35
Sex and Diffusion Tensor Imaging of White Matter in Schizophrenia: A Systematic Review Plus Meta-analysis of the Corpus Callosum. 61
28449132 2018
36
Exome Sequencing Identifies TENM4 as a Novel Candidate Gene for Schizophrenia in the SCZD2 Locus at 11q14-21. 61
30745909 2018
37
Comorbid Diagnosis of Psychotic Disorders in Borderline Personality Disorder: Prevalence and Influence on Outcome. 61
29593589 2018
38
Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders. 61
29796036 2018
39
Imaging Violence in Schizophrenia: A Systematic Review and Critical Discussion of the MRI Literature. 61
30083111 2018
40
Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis. 61
28980344 2017
41
Guidelines for the Pharmacotherapy of Schizophrenia in Adults. 61
28703015 2017
42
Identification of the delivery of cognitive behavioural therapy for psychosis (CBTp) using a cross-sectional sample from electronic health records and open-text information in a large UK-based mental health case register. 61
28716789 2017
43
The role of shame in people with a diagnosis of schizophrenia. 61
28105670 2017
44
Layer 3 Excitatory and Inhibitory Circuitry in the Prefrontal Cortex: Developmental Trajectories and Alterations in Schizophrenia. 61
27455897 2017
45
Schizophrenia Associated with Epileptiform Discharges without Seizures Successfully Treated with Levetiracetam. 61
28228737 2017
46
Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. 61
27926742 2017
47
Schizophrenia and sleep disorders: links, risks, and management challenges. 61
29033618 2017
48
Aberrant intra-salience network dynamic functional connectivity impairs large-scale network interactions in schizophrenia. 61
27825906 2016
49
What are the top 10 physical activity research questions in schizophrenia? 61
26728764 2016
50
Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia. 61
26630458 2016
51
Cognitive remediation in schizophrenia: A methodological appraisal of systematic reviews and meta-analyses. 61
26828372 2016
52
The search for new biomarkers for cognition in schizophrenia. 61
29114461 2015
53
Psychosocial functioning in relation to symptomatic remission: A longitudinal study of first episode schizophrenia. 61
26647865 2015
54
New Targets for Prevention of Schizophrenia: Is It Time for Interventions in the Premorbid Phase? 61
25925393 2015
55
Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. 61
25863358 2015
56
An eye-tracking investigation of intentional motion perception in patients with schizophrenia. 61
25247443 2015
57
How connected are people with schizophrenia? Cell phone, computer, email, and social media use. 61
25563669 2015
58
Effects of cognitive rehabilitation training on schizophrenia: 2 years of follow-up. 61
26629117 2015
59
Development of a Community-Based Rehabilitation Intervention for People with Schizophrenia in Ethiopia. 61
26618915 2015
60
Prevalence and attributes of criminality in patients with schizophrenia. 61
24879076 2015
61
Cannabis and schizophrenia. 61
25314586 2014
62
Impaired integration of disambiguating evidence in delusional schizophrenia patients. 61
25065271 2014
63
Childhood attachment and schizophrenia: the "attachment-developmental-cognitive" (ADC) hypothesis. 61
24957505 2014
64
Childhood Epstein-Barr Virus infection and subsequent risk of psychotic experiences in adolescence: a population-based prospective serological study. 61
25048425 2014
65
'Schizophrenia is a dirty word': service users' experiences of receiving a diagnosis of schizophrenia. 61
25237536 2014
66
Psychosocial support and cognitive deficits in adults with schizophrenia. 61
23828764 2014
67
Copy number variation in obsessive-compulsive disorder and tourette syndrome: a cross-disorder study. 61
25062598 2014
68
Education and the public's desire for social distance from people with depression and schizophrenia: the contribution of emotional reactions and causal attributions. 61
23887248 2014
69
Effects of a mindfulness-based psychoeducation programme for Chinese patients with schizophrenia: 2-year follow-up. 61
24809397 2014
70
Integrated pathway-based approach identifies association between genomic regions at CTCF and CACNB2 and schizophrenia. 61
24901509 2014
71
[Variants of cognitive development in children and adolescents with different forms of schizophrenia]. 61
25726779 2014
72
Minimizing false positive error with multiple performance validity tests: response to Bilder, Sugar, and Hellemann (2014 this issue). 61
25491180 2014
73
The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. 61
23123365 2014
74
[NMDA-type glutamate receptor and schizophrenia]. 61
25069261 2013
75
Validation of the modified DUKE-UNC Functional Social Support Questionnaire in patients with schizophrenia. 61
23229203 2013
76
[Clinical features and comorbidities of Asperger syndrome in children]. 61
24034914 2013
77
Social support and religion: mental health service use and treatment of schizophrenia. 61
22855264 2013
78
[The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients]. 61
24946464 2013
79
Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. 61
23842008 2013
80
Schizophrenia-related phenomena that challenge prediction error as the basis of cognitive functioning. 61
23663652 2013
81
Understanding the communicative impairments in schizophrenia: a preliminary study. 61
23562700 2013
82
Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. 61
22510462 2013
83
Cuprizone-induced demyelination in mice: age-related vulnerability and exploratory behavior deficit. 61
23558591 2013
84
Has the generalized deficit become the generalized criticism? 61
23236079 2013
85
Comparison of treatment response in second-episode versus first-episode schizophrenia. 61
23277247 2013
86
The dietary pattern of patients with schizophrenia: a systematic review. 61
23153955 2013
87
Can we trust the internet to measure psychotic symptoms? 61
23936652 2013
88
[Risk factors of schizophrenia development in patients with amphetamines dependence and psychosis (amphetamine-induced psychosis and schizophrenia), and without psychosis]. 61
23214160 2012
89
The World Health Organization Short Disability Assessment Schedule: a validation study in patients with schizophrenia. 61
21489417 2012
90
Wisconsin Card Sorting Test scores and clinical and sociodemographic correlates in Schizophrenia: multiple logistic regression analysis. 61
23135537 2012
91
Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. 61
22802938 2012
92
Oscillatory cortical network involved in auditory verbal hallucinations in schizophrenia. 61
22844436 2012
93
The temporal organization of functional brain connectivity is abnormal in schizophrenia but does not correlate with symptomatology. 61
20541442 2011
94
Altered cortical network dynamics: a potential intermediate phenotype for schizophrenia and association with ZNF804A. 61
21810628 2011
95
Association of GRIN1 and GRIN2A-D with schizophrenia and genetic interaction with maternal herpes simplex virus-2 infection affecting disease risk. 61
21919190 2011
96
A computational approach to quantifiers as an explanation for some language impairments in schizophrenia. 61
21880327 2011
97
Early risk factors for criminal offending in schizophrenia: a 35-year longitudinal cohort study. 61
20607212 2011
98
The World Health Organization Quality of Life Scale Brief Version: a validation study in patients with schizophrenia. 61
21290191 2011
99
Isolating nasal olfactory stem cells from rodents or humans. 61
21876529 2011
100
Optogenetic neuronal control in schizophrenia. 61
21482453 2011
101
Association of religion with delusions and hallucinations in the context of schizophrenia: implications for engagement and adherence. 61
21131180 2011
102
Stereological approaches to identifying neuropathology in psychosis. 61
20678756 2011
103
Birth weight, schizophrenia, and adult mental disorder: is risk confined to the smallest babies? 61
20819986 2010
104
Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. 61
20819982 2010
105
Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. 61
20555313 2010
106
Obsessive-compulsive symptoms in schizophrenia: their relationship with clinical features and pharmacological treatment. 61
20644358 2010
107
Proton MRS in twin pairs discordant for schizophrenia. 61
18645571 2010
108
Core of schizophrenia: estrangement, dementia or neurocognitive disorder? 61
20639690 2010
109
Family-level predictors and correlates of the duration of untreated psychosis in African American first-episode patients. 61
19833482 2009
110
Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia. 61
19394958 2009
111
Profile of auditory information-processing deficits in schizophrenia. 61
18990453 2009
112
Thought disorder in Asperger syndrome and schizophrenia: issues in the differential diagnosis. A series of case reports. 61
17965991 2009
113
Insight and treatment outcome with cognitive-behavioral social skills training for older people with schizophrenia. 61
20157862 2009
114
Role of the central cholinergic system in the therapeutics of schizophrenia. 61
19506725 2008
115
[Mothers' perception of their closeness-caregiving and intrusiveness toward adult sons with a diagnosis of schizophrenia or drug addiction]. 61
19899569 2008
116
[Psychopathology of schizophrenia and brain imaging]. 61
18461545 2008
117
The service needs of mothers with schizophrenia: a qualitative study of perinatal psychiatric and antenatal workers. 61
18291300 2008
118
The DISC locus in psychiatric illness. 61
17912248 2008
119
Familial liability and schizophrenia phenotypes: a polydiagnostic approach. 61
17765478 2007
120
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. 61
18052569 2007
121
Visual-perceptual abilities in healthy controls, depressed patients, and schizophrenia patients. 61
17517458 2007
122
Lithium for schizophrenia. 61
17636738 2007
123
Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. 61
17310386 2007
124
Reduced anterior internal capsule and thalamic volumes in first-episode psychosis. 61
16793239 2006
125
[Religiousness of patients with diagnosis of schizophrenia. Wide-ranging studies]. 61
17217233 2006
126
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. 61
16894060 2006
127
Convergent evidence for 2',3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene for schizophrenia. 61
16389193 2006
128
Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. 61
16318875 2006
129
[Influence of anxiety on cognitive functions' disturbances in adolescents and young adults diagnosed with paranoid schizophrenia]. 61
17474174 2006
130
[Homicide by mentally ill: clinical and criminological analysis]. 61
16598958 2005
131
Quality of life of patients with schizophrenia 2. 61
16761659 2005
132
A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in acute patients with schizophrenia: outcome at 24 months. 61
16095471 2005
133
Hippocampus and amygdala volumes in schizophrenia and other psychoses in the Northern Finland 1966 birth cohort. 61
15885519 2005
134
Vitamin D receptor variants in 192 patients with schizophrenia and other psychiatric diseases. 61
15854747 2005
135
Neurologic presentation of celiac disease. 61
15825133 2005
136
Drivers of workplace discrimination against people with disabilities: the utility of Attribution Theory. 61
16006678 2005
137
Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. 61
15364042 2004
138
Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice. 61
15148266 2004
139
AMPA receptor potentiators for the treatment of CNS disorders. 61
15180479 2004
140
[Cognitive-behavioral therapy for auditory hallucinations resistant to neuroleptic treatment]. 61
15209053 2004
141
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. 61
15279040 2004
142
[Maxillofacial trauma by defenestration: 64 cases]. 61
14679344 2003
143
Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. 61
12931208 2003
144
Testing hypotheses about the relationship between cannabis use and psychosis. 61
12821204 2003
145
Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. 61
12691783 2003
146
[Mental health in a municipality of the State of Querétaro: a community-based psychiatric research model]. 61
12754943 2003
147
Musical hallucinations in schizophrenia. 2. Relations with verbal hallucinations. 61
12766321 2003
148
Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. 61
12926541 2003
149
Lithium for schizophrenia. 61
12917990 2003
150
[Quality of life of schizophrenia patients and health related problem solving skills--comparison between the group of patient participated in social skills training and psychoeducation group]. 61
12491982 2002
151
Improving social functioning in schizophrenia by playing the train game. 61
12096159 2002
152
Delusional disorder: molecular genetic evidence for dopamine psychosis. 61
12007750 2002
153
Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. 61
11777738 2001
154
Estimated yield of early detection of prodromal or first episode patients by screening first degree relatives of schizophrenic patients. 61
11595388 2001
155
Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia. 61
11605084 2001
156
Treatment of the schizophrenia prodrome: is it presently ethical? 61
11479063 2001
157
Platelet serotonin concentrations in medicated schizophrenic patients. 61
11444685 2001
158
The interface of psychiatric disorders and diabetes mellitus. 61
11353589 2001
159
Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorder. 61
11525420 2001
160
[Anesthesia for electroconvulsive therapy: propofol versus thiopental]. 61
11488251 2001
161
Correlations between clinical and historical variables, and cerebral structural variables in people with mild intellectual disability and schizophrenia. 61
11298247 2001
162
Paediatric psychopharmacology: closing the gap between science and practice. 61
11336602 2001
163
Natural course of schizophrenia: 2-year follow-up study in a rural Chinese community. 61
11157428 2001
164
Invited commentary on: Natural course of schizophrenia: 2-year follow-up study in a rural Chinese community. 61
11157429 2001
165
A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia. 61
11153542 2001
166
[Schizophrenia 2]. 61
11383275 2001
167
[Microdeletion 22q11: apropos of case of schizophrenia in an adolescent]. 61
11294038 2001
168
Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. 61
11058482 2000
169
Blockade of phencyclidine-induced effects by a nitric oxide donor. 61
10882384 2000
170
Proton magnetic resonance spectroscopy of lenticular nuclei in simple schizophrenia. 61
10958147 2000
171
Clozapine and negative symptoms. An open study. 61
10836486 2000
172
[Vulnerability to schizophrenia. III: Importance and limits of the Identical Pairs Continuous Performance Test]. 61
10858916 2000
173
Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. 61
10650444 2000
174
Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: An unbiased cell-counting study. 61
10502308 1999
175
The three-syndrome model of schizophrenia: meta-analysis of an artefact. 61
10507515 1999
176
Effects of the serotonin2A/2C receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex. 61
10581647 1999
177
Olanzapine: new preparation. Keep an eye on this neuroleptic. 61
11503836 1999
178
Olanzapine transfer by human placenta. 61
10499158 1999
179
Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs. 61
10368855 1999
180
Environmental interventions in schizophrenia. 2: The community level. 61
10495650 1999
181
Course of substance abuse in patients with and without schizophrenia. 61
10189515 1999
182
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. 61
10416727 1999
183
Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. 61
9842773 1998
184
Visual scanning of faces correlates with schizophrenia symptomatology. 61
9789881 1998
185
The structure of psychosis: latent class analysis of probands from the Roscommon Family Study. 61
9633666 1998
186
The Maudsley Family Study. I: Structural brain changes on magnetic resonance imaging in familial schizophrenia. 61
9460093 1997
187
Chronic haloperidol treatment does not affect structure of attention in schizophrenia. 61
9176927 1997
188
Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. 61
8761867 1996
189
Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. 61
9231318 1996
190
Language of dysfunction in schizophrenia. 61
8776437 1996
191
Glutamate receptor dysfunction and schizophrenia. 61
7492260 1995
192
The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. 61
8747172 1995
193
A phenomenological study of families and psychoeducation support groups. 61
8847674 1995
194
Medical disorders in the schizophrenic patient. 61
7591491 1995
195
[A theory explaining the relation between "egorrhea symptoms" and "symptoms of being influenced" more efficiently than the existing theories--from the viewpoint of "experiencial type" as opposed to symptomatological direction]. 61
7732149 1995
196
Schizophrenia family work: mental health nurses delivering an innovative service. 61
7844764 1994
197
Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. 61
7972857 1994
198
[Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients]. 61
7828511 1994
199
Independent diagnoses of adoptees and relatives as defined by DSM-III in the provincial and national samples of the Danish Adoption Study of Schizophrenia. 61
8192548 1994
200
Electroconvulsive therapy in a psychiatric intensive care unit. 61
7993281 1994
201
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. 61
8122957 1994
202
MMPI correlates of psychotherapy compliance among obsessive-compulsives. 61
8511225 1993
203
Traumatic war. Stress & schizophrenia. 61
1613685 1992
204
[Study on argyrophilic inclusions of multisystem atrophy (Oppenheimer)]. 61
1654964 1991
205
Is schizophrenia caused by excessive production of interleukin-2 and interleukin-2 receptors by gastrointestinal lymphocytes? 61
2062256 1991
206
Motor, volitional and behavioural disorders in schizophrenia. 2: The 'conflict of paradigms' hypothesis. 61
2036530 1991
207
Antidepressant for substance-abusing schizophrenic patients: a minireview. 61
2008536 1991
208
[Possible involvement of phospholipase A2 in the pathogenesis of schizophrenia]. 61
2354835 1990
209
Review of a mother-baby unit in a psychiatric hospital. 61
2334379 1990
210
Report of a workshop on genetic linkage studies in schizophrenia. 61
2077644 1990
211
[Unfavorable course of recurrent (schizoaffective) schizophrenia]. 61
2158733 1990
212
Gender and schizophrenia outcome: a clinical trial of an inpatient family intervention. 61
2197716 1990
213
Findings significant with respect to short- and medium-term outcome in schizophrenia--a preliminary report. 61
2748859 1989
214
Folic acid and psychopathology. 61
2682787 1989
215
Children of mentally ill mothers: social situation and psychometric testing of mental development. 61
2473514 1989
216
The validity of DSM-III borderline personality disorder. A phenomenologic, family history, treatment response, and long-term follow-up study. 61
6849616 1983
217
Discussion of Alfred Alder's preface to The Diary of Vaslav Nijinsky. 61
7018451 1981
218
The nosologic validity of paranoia (simple delusional disorder). A review. 61
7387341 1980
219
[Concerning the borderline (author's transl)]. 61
6898511 1980
220
[Independence of the slowly progressive form of schizophrenia]. 61
7010849 1980
221
Perspectives in chemotherapy of schizophrenic psychoses. 61
45563 1979
222
[The psychodynamics of schizophrenia. 2. The current interpretation of the deficit theory, psychodynamic concepts outside psychoanalytic studies, theories on interpersonal dynamics, resp. family dynamics]. 61
422098 1979
223
Medico-social evaluation of the long-term pharmacotherapy of schizophrenia. Comparative study of fluphenazine and pimozide. 61
401349 1979
224
Developments in family treatment of schizophrenia. 61
493431 1979
225
Gregory Bateson and the mathematicians: from interdisciplinary interaction to societal functions. 61
325068 1977
226
Is disordered thinking unique to schizophrenia? 61
836125 1977
227
Schizophrenia. 2. Psycho-analytical and other opinions. 61
1121434 1975
228
Elementary psychiatry; schizophrenia. 2. 61
5245241 1968
229
[Pseudoneurotic schizophrenia. 2. Clinical contribution]. 61
5879958 1965
230
[The immuno-electrophoretic picture of infantile schizophrenia (2 cases)]. 61
13700660 1960

Variations for Schizophrenia 2

Expression for Schizophrenia 2

Search GEO for disease gene expression data for Schizophrenia 2.

Pathways for Schizophrenia 2

GO Terms for Schizophrenia 2

Sources for Schizophrenia 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....